Invest Alpha Pro

Notable Earnings for the Week: Nov 2–6th, 2026. 🍎 $AAPL headlines Monday after the close Revenue should land near top of guide. Margins are the test. The breakdown 👇 •EPS est: $1.98 vs $1.85 yr ago •Rev est: $113.3B, top of guide •Gross margin guide: 47–48% vs 50.1% •Implied move: ±4.2% Supporting cast: • $PLTR Mon AMC: ±12.4% implied, EPS est $0.33. • $AMD Tue AMC: ~$13B rev guide, EPS est $1.68. • $ANET Tue AMC: ±10.9% implied, AI networking. • $ARM Wed AMC: ±15.1% implied, week's biggest. • $APP Wed AMC: EPS est $3.94 vs $2.45 yr ago. • $IREN Thu AMC: first FY27 print, AI cloud check. Why it matters: memory costs are hitting Apple's margins while AMD, Arm and Arista show whether AI spend is still accelerating. Then Friday's 8:30am ET jobs report gets the last word. JOLTS Tue, ADP Wed. Which print moves your portfolio most? I Long $PLTR $APP $IREN | NFA | DYOR

$FISV Q3: beat, guide holds, stock pops. Ugly $5.9B GAAP loss, but the core beat. The breakdown 👇 •Adj. EPS: $1.75 vs $1.72 est. •Adj. Rev: $4.85B vs $4.84B est. •Organic: flat (Merchant -2%, Fin +2%) •FY26 EPS guide: $7.20–$7.40, affirmed •Stock: +7% premarket Why it matters: after a 62% slide in a year, no new guidance cut is the win. Margins still shrinking: Merchant 28.7% vs 37.2% a year ago. Watch the 8am call for what drove the $11.17 GAAP loss per share.

🛍️ $SHOP Q3: EPS beat, cash machine. Revenue hit the number. Cash flow blew past it. The breakdown 👇 •Adj. EPS: $0.49 vs $0.46 est. •Revenue: $3.74B (+32%), in line •GMV: $119.1B (+29%), FCF margin 22% •Q4 guide: low 30s% rev, high 20s% GP Why it matters: Payments now drive the story (merchant solutions +35% vs subscriptions +20%). That mix pinches gross margin (GP +28%), but opex leverage turned it into $816M of free cash flow. At 100x earnings, is 30%+ growth at Shopify's scale enough?

🛢️ $MPC Q3: Crushes estimates, adds $5B buyback. Q2's blowout got topped again: margins up, refineries at 100%, and more cash headed back to shareholders. The breakdown 👇 •Adj. EPS: $26.93 vs $24.47 est. (+795% YoY) •Rev: $56.49B vs $46.04B est. (+58% YoY) •R&M margin: $45.70/bbl vs $44.76 est. •Q4 guide: 3,080 mbpd throughput, $230M turnarounds Why it matters: $3.3B returned, $5B more authorized, and a $4.2B Mid Con sale funds a Gulf Coast push. Mgmt is betting margins stay elevated.

$PFE Q3: Beat and raise as COVID fades. Street braced for $0.73. Pfizer did $0.87. The breakdown 👇 •Adj. EPS: $0.87 vs $0.73 est. •Revenue: $16.6B vs $15.9B est. •Ex-COVID rev: +7% operationally •FY26 guide: raised to $2.95–$3.05 EPS Why it matters: launched and acquired products grew 32%, outrunning the COVID fade. But the raised midpoint ($3.00) barely tops the $2.96 est., and the 2028 patent cliff is still the test. New CFO Cecile Guegan took over Nov. 1.

$RACE Q3: Beat + 2nd guidance raise. Fewer cars, China down 42%, and Ferrari raised guidance anyway. The breakdown 👇 •EPS: $2.73 vs $2.66 est •Rev: $2.12B vs $2.11B est •Cars/parts: $1.77B, +7% •FY guide: EPS ≥$11.01 (was ≥$10.82) Why it matters: shipments slipped to 3,368 units, yet EPS jumped 14% YoY. F80 mix and personalizations drove EBITDA margin up 180 bps to 39.7%, FCF rose 43%, and the order book now reaches into 2028. Ferrari doesn't need volume. It needs pricing power, and it has it.

$DT beats, then trims its profit outlook. Sales guide goes up, EPS guide comes down. The breakdown 👇 •EPS: $0.54 vs $0.49 est. •Rev: $579.9M vs $568M est. (+17% y/y) •ARR: $2.21B, +16% y/y •FY27: rev guide raised, EPS cut to $1.88–1.90 Arize is the swing factor: it adds 200 bps to ARR growth but costs 175 bps of margin this year. Mgmt also bought back $246M and added a fresh $1B authorization. Investor Day Feb 16 is where the Rule of 50 math gets tested.

$ETN Q3: Beat and raise on AI power. Down 14% in a month. Data centers answered. The breakdown 👇 •Adj. EPS: $3.68 vs $3.54 est. •Rev: $8.95B vs $8.51B est., +28% YoY •Elec. Americas: $4.17B vs $4.00B est. •FY26 guide: $13.70–13.80 vs $13.60 est. Why it matters: record orders, Electrical backlog +46%, and a record 25.3% margin. The crack: FCF $1.03B vs $1.31B est., and Q4 guide only in line.

$ZBRA Q3: Beat on both lines Frontline ripped 35%. Automation and margins didn't. The breakdown 👇 •Adj. EPS: $4.95 vs $4.90 est. •Rev: $1.6B vs $1.56B est., +22% YoY •Frontline: $949M vs $881M est., +35% •Q4 EPS guide: $5.00–$5.40 vs $5.18 est. Why it matters: FY26 FCF guide raised to $1B+, but gross margin fell 230 bps and AVA missed by $24M.

🧪 $WAT beats and raises again. BD deal is paying off, every guide line raised. Stock shrugs. The breakdown 👇 •Adj. EPS: $4.10 vs $4.00 est. •Rev: $1.77B vs $1.75B est. •Organic: +10% cc, ASD +8% •FY EPS guide: $14.60–$14.70 (raised) •Stock: +0.1% premarket Why it matters: legacy Waters grew 10% cc on its own (GLP-1, PFAS, India generics) and the BD units landed ahead of plan, lifting the FY revenue guide by $43M. Catch: Q4 EPS guide of $4.58–$4.68 is only 1–3% growth.

✈️ $BETA smashes Q3: record revenue, +98% Y/Y. Street expected 21% growth. BETA delivered 98% and raised the full year. The breakdown 👇 •EPS: -$0.51 vs -$0.59 est. •Revenue: $17.7M vs $10.8M est. •Backlog: $4.0B+ (1,040 aircraft), past year-end target. •FY26 guide: $52M–$57M, up from $42M–$50M. Why it matters: first eVTOL cleared by the FAA to fly customers onboard, and $1.34B in cash covers a $97M quarterly adj. EBITDA loss. Is this the quarter BETA goes from story stock to execution story?

🔔 Closing Bell: The tech rout isn't done. Oil crashed, factories beat, Nasdaq opened +1.4%. Friday's rout looked over. Chips said no. The breakdown 👇 •Driver: $MRVL -13% on $LITE deal, $ORCL -8% on $20B raise. •Nasdaq -1.07% | S&P -0.51% | Dow +0.41% | R2K -0.21%. •ISM Mfg: 55.5 vs 54.6 est, prices paid cooled to 75.2. •Dec hike odds: 77% vs 49% a month ago. •Oil: WTI -7.6% on US-Iran peace hopes. •Crypto: $BTC $77.7K (-1.3%), $ETH $2.28K •After hours: $AAPL beats, shares flat. Growth, inflation and oil all broke right, and AI still sold. The market is pricing the cost of the buildout. Midterms tomorrow, jobs Friday. Buy the dip or wait it out? I Long $MRVL $ORCL $NVDA $ETH. NFA

$VRTX tops on sales, edges up guide Sales beat, EPS missed by 2 cents, and the guide trails the Street. The breakdown 👇 •Adj. EPS: $4.76 vs $4.78 est •Rev: $3.44B vs $3.42B est •Alyftrek: $706M vs $247M LY •FY guide: $13.15–13.25B rev Next gen CF is taking the baton: Alyftrek nearly tripled while Trikafta slid 8%. Casgevy hit $99M. Povetacicept's FDA decision for IgAN lands Nov 30.

$ON beats, but the stock slips -3.32% AH. Beat on both lines with AI power demand surging, yet shares fade. The breakdown 👇 •Adj. EPS: $0.90 vs $0.87 est •Rev: $1.72B, +11% YoY, beat est •AI DC: +175% YoY, +39% QoQ •Q4 guide: $1.72–1.82B rev •Stock: -3.32 AH Power solutions (PSG) +21% drove it, with gross margin 41.2% vs 38% a year ago. onsemi is buying Ferric for AI chip power delivery and raised its 2030 AI data center target to $3B+.

🛡️ $LIFE crushes Q3: revenue up 151% Sales blew past the Street, but GAAP profit shrank. Growth is the story. The breakdown 👇 •Adj. EPS: $0.49 vs $0.35 est •Rev: $235.2M vs $169.0M est •Policies: 142K, +189% YoY •Q4 guide: $220–224M rev GAAP EPS fell to $0.07 from $0.27 and revenue per policy dropped 13% as the third party channel (+209%) outgrew direct. Third straight triple digit growth quarter, plus a new $100M buyback.

🍏 $AAPL beats in Ternus' first quarter Record Sept qtr, yet shares slip 1% after hours. China is the crack. The breakdown 👇 •EPS: $2.10 vs $2.00 est •Rev: $114.5B vs $113.5B est •iPhone: $57.6B vs $56.5B est •Guide: Dec qtr on 5pm ET call •Stock: -1% after hours China missed at $17.5B vs $18.8B est. Services $31.6B, in line. Gross margin 47.9%, top of guide. Only 9 days of iPhone 18 Pro sales are in here, so the Dec guide, memory costs and Duo demand decide the next leg. Does a China miss matter at a $5T valuation?

🧬 $BMRN cracks a $1B quarter, guide cut. Beat on both lines, but the guide cut wins after hours. The breakdown 👇 •Adj. EPS: $0.23 vs $0.12 est. •Rev: $1.025B vs $1.02B est., +32% •Metabolic: $744M, +44% Y/Y •FY guide: EPS $2.80–3.10 (was $4.90–5.10) •Stock: -2.4% AH Why it matters: Amicus drugs drove the top line and Voxzogo grew 12% to $245M. Most of the EPS cut is the $1.50/sh Alesta IPR&D charge; the real tell is the revenue guide trimmed to $3.8–3.9B on order timing.

📺 $ROKU Q3: blowout EPS, stock doesn't care. Roku more than doubled the EPS estimate, yet shares barely moved. Fox's $160 deal sets the price. The breakdown 👇 •EPS: $1.20 vs $0.53 est. •Revenue: $1.50B vs $1.41B est. (+24% YoY) •Net income: up more than 7x YoY •Guidance: none, paused for the Fox deal •Stock: flat AH near $155.50 vs $160 deal price. Why it matters: another big beat shows Roku can stand on its own if regulators stall the deal. The roughly 3% gap to $160 is now a bet on the deal closing.

$FN Q1: record quarter, guide goes higher. Wall St wanted $4.19 and $1.40B. Fabrinet beat both and guided above where the Street sat. The breakdown 👇 •Adj. EPS: $4.34 vs $4.19 est. •Revenue: $1.47B vs $1.40B est. (+51% YoY) •Buyback: +$103M, total authorization now $637M •Q2 guide: $1.60–1.65B rev, $4.77–4.92 adj. EPS •Stock: fell 6.4% to $326 into the print. Why it matters: revenue beat the top of $FN's own range by about $50M, a day after the stock sold off into a record quarter.

🚀 $PLTR Q3: beat, raise, historic flip Revenue nearly doubled. Stock barely moved. The breakdown 👇 •Adj. EPS: $0.44 vs $0.41 est •Rev: $2.31B vs $2.18B est, +96% Y/Y •U.S. Comm: +148%, tops U.S. Gov •FY Guide: $8.53B vs $8.2B est •Stock: flat after hours U.S. commercial passing government is the real headline: Palantir is no longer just a defense stock. But at 114x FY26 earnings, beat-and-raise is table stakes. The market is already pricing 2027. Is the flat reaction a buying window or a warning? I Long $PLTR | NFA

🚀 $AEHR smashes Q1, lifts FY27 guide Revenue tripled. EPS 2.5x est. The breakdown 👇 •Adj. EPS: $0.28 vs $0.11 est. •Rev: $33.0M vs $27.5M est. (+200% YoY) •Bookings: $46.7M, 1.4x book-to-bill •FY27 guide: $150M rev (was $130–150M) •Stock: -6% into print, AH pending Why it matters: effective backlog hit $109.3M, and Aehr now sees production orders possible from a dozen plus customers, up from a handful. AI burn in is broadening past its first hyperscaler customer. Picks and shovels AI compounder, or still too lumpy to own?